Cardiovascular risk in patients submitted to liver transplantation.
OBJECTIVE
To determine the prevalence of cardiovascular risk in patients undergoing liver transplantation according to the Framingham score, and to evaluate possible associations with traditional and non-traditional risk factors.


METHODS
Cross-sectional study in which patients undergoing liver transplantation were stratified by cardiovascular risk according to the Framingham score. Demographic, socioeconomic, clinical, and anthropometric variables were collected to assess the association with cardiovascular risk factors using univariate and multivariate statistical analyses.


RESULTS
A total of 115 patients were evaluated, of which 46.1% showed medium or high risk for the occurrence of cardiovascular events over ten years. The mean percentage risk of evaluated patients was of 9.5 ± 7.8%. Male gender (OR: 4.97; CI: 1.92-12.85; p < 0.01), older age (OR: 1,09; CI: 1.04-1.13; p < 0.01), and higher BMI at the moment of assessment (1.09; CI: 0.99-1.20; p = 0.03) were factors associated with medium and high cardiovascular risk. A higher percentage of cardiovascular risk was also associated with cyclosporine use (p = 0.01).


CONCLUSIONS
The probability of occurrence of cardiovascular events in the assessed patients undergoing liver transplantation was higher than that in the Brazilian population. Special attention should be paid to this population, especially in relation to potentially modifiable factors associated to higher BMI and cyclosporine use.
Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. 　helemsena@gmail.com
Hélem de Sena
Hde S
Ribeiro
Lucilene Rezende
LR
Anastácio
Lívia Garcia
LG
Ferreira
Agnaldo Soares
AS
Lima
Maria Isabel Toulson Davisson
MI
Correia
D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000209:etiology*; D003430:Cross-Sectional Studies; D016572:Cyclosporine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D012959:Socioeconomic Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine